ID   LC-2/ad-cis
AC   CVCL_C4AM
DR   Wikidata; Q116049669
RX   PubMed=25826333;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1373 ! LC-2/ad
SX   Female
AG   51Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   PubMed=25826333; DOI=10.1371/journal.pone.0121460;
RA   Katono K., Sato Y., Jiang S.-X., Kobayashi M., Nagashio R., Ryuge S.,
RA   Fukuda E., Goshima N., Satoh Y., Saegusa M., Masuda N.;
RT   "Prognostic significance of MYH9 expression in resected non-small cell
RT   lung cancer.";
RL   PLoS ONE 10:E0121460-E0121460(2015).
//